Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. As of May 21, 2025, Acelyrin, Inc. operates as a subsidiary of Alumis Inc.
Add an action for SLRN.US, or sign in to see your action list.
| Name | Title | Year Born |
|---|---|---|
| Ms. Mina Kim J.D. | CEO & Director | 1974 |
| Dr. Shephard Mpofu M.D. | Chief Medical Officer | 1967 |
| Mr. Tyler Marciniak | Vice President of Investor Relations, Communications & Corporate Operations | NA |
| Mr. K. Amar Murugan J.D. | Chief Legal Officer | 1976 |
| Ms. Kelly Chow | Chief People Officer | NA |
| Mr. Kenneth A. Lock | Chief Commercial Officer | 1974 |
| Ms. Patricia A. Turney | Chief Technical Operations Officer | 1967 |
Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.